Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Chromosomal aberrations in UVB-induced tumors of immunosuppressed mice.

Dworkin AM, Tober KL, Duncan FJ, Yu L, VanBuskirk AM, Oberyszyn TM, Toland AE.

Genes Chromosomes Cancer. 2009 Jun;48(6):490-501. doi: 10.1002/gcc.20657.

2.

Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet-B (UVB) -induced nonmelanoma skin cancer (NMSC).

Martin J, Duncan FJ, Keiser T, Shin S, Kusewitt DF, Oberyszyn T, Satoskar AR, VanBuskirk AM.

FASEB J. 2009 Mar;23(3):720-30. doi: 10.1096/fj.08-119628. Epub 2008 Oct 24.

PMID:
18952710
3.

The hairless mouse in skin research.

Benavides F, Oberyszyn TM, VanBuskirk AM, Reeve VE, Kusewitt DF.

J Dermatol Sci. 2009 Jan;53(1):10-8. doi: 10.1016/j.jdermsci.2008.08.012. Epub 2008 Oct 19. Review.

4.

Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice even with co-administration of cyclosporine A.

Wulff BC, Kusewitt DF, VanBuskirk AM, Thomas-Ahner JM, Duncan FJ, Oberyszyn TM.

J Invest Dermatol. 2008 Oct;128(10):2467-73. doi: 10.1038/jid.2008.121. Epub 2008 May 8.

5.

Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis.

Duncan FJ, Wulff BC, Tober KL, Ferketich AK, Martin J, Thomas-Ahner JM, Allen SD, Kusewitt DF, Oberyszyn TM, Vanbuskirk AM.

Am J Transplant. 2007 Dec;7(12):2693-703. Epub 2007 Oct 17.

6.

Depletion of CD4+ cells exacerbates the cutaneous response to acute and chronic UVB exposure.

Hatton JL, Parent A, Tober KL, Hoppes T, Wulff BC, Duncan FJ, Kusewitt DF, VanBuskirk AM, Oberyszyn TM.

J Invest Dermatol. 2007 Jun;127(6):1507-15. Epub 2007 Mar 15.

7.

Human CD4+CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance.

Xu Q, Lee J, Jankowska-Gan E, Schultz J, Roenneburg DA, Haynes LD, Kusaka S, Sollinger HW, Knechtle SJ, VanBuskirk AM, Torrealba JR, Burlingham WJ.

J Immunol. 2007 Mar 15;178(6):3983-95. Erratum in: J Immunol. 2007 Jun 1;178(11):7488. Roennburg, Drew A [corrected to Roenneburg, Drew A].

8.
9.
10.

IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice.

Dierksheide JE, Baiocchi RA, Ferketich AK, Roychowdhury S, Pelletier RP, Eisenbeis CF, Caligiuri MA, VanBuskirk AM.

Blood. 2005 Feb 15;105(4):1558-65. Epub 2004 Oct 21.

PMID:
15498860
11.

A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.

Parihar R, Nadella P, Lewis A, Jensen R, De Hoff C, Dierksheide JE, VanBuskirk AM, Magro CM, Young DC, Shapiro CL, Carson WE 3rd.

Clin Cancer Res. 2004 Aug 1;10(15):5027-37.

12.

Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation.

Pelletier RP, Hennessy PK, Adams PW, VanBuskirk AM, Ferguson RM, Orosz CG.

Am J Transplant. 2002 Feb;2(2):134-41.

13.

A role for TGFbeta and B cells in immunologic tolerance after intravenous injection of soluble antigen.

Valujskikh A, VanBuskirk AM, Orosz CG, Heeger PS.

Transplantation. 2001 Aug 27;72(4):685-93.

PMID:
11544432
14.

A gene polymorphism associated with posttransplant lymphoproliferative disorder.

VanBuskirk AM, Malik V, Xia D, Pelletier RP.

Transplant Proc. 2001 Feb-Mar;33(1-2):1834. No abstract available.

PMID:
11267533
15.

Immunoregulation in liver transplant recipients: possible evidence of tolerance by DTH assay.

Geissler F, Jankowska-Gan E, Sollinger H, Kalayoglu M, VanBuskirk AM, Orosz CG, Burlingham W.

Transplant Proc. 2001 Feb-Mar;33(1-2):1377. No abstract available.

PMID:
11267335
16.

Human allograft acceptance is associated with immune regulation.

VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, Chin T, Kusaka S, Geissler F, Pelletier RP, Orosz CG.

J Clin Invest. 2000 Jul;106(1):145-55.

17.

Transforming growth factor-beta and interleukin-10 subvert alloreactive delayed type hypersensitivity in cardiac allograft acceptor mice.

Bickerstaff AA, VanBuskirk AM, Wakely E, Orosz CG.

Transplantation. 2000 Apr 15;69(7):1517-20.

PMID:
10798784
18.

Trans vivo analysis of human delayed-type hypersensitivity reactivity.

Carrodeguas L, Orosz CG, Waldman WJ, Sedmak DD, Adams PW, VanBuskirk AM.

Hum Immunol. 1999 Aug;60(8):640-51.

PMID:
10439310
19.

Cardiac allograft tolerance: failure to develop in interleukin-4-deficient mice correlates with unusual allosensitization patterns.

Sirak JH, Orosz CG, Roopenian DC, Wakely E, VanBuskirk AM.

Transplantation. 1998 May 27;65(10):1352-6.

PMID:
9625018
20.

Immune mechanisms of acute rejection.

Orosz CG, VanBuskirk AM.

Transplant Proc. 1998 May;30(3):859-61. Review.

PMID:
9595126
22.

Transplantation immunology.

VanBuskirk AM, Pidwell DJ, Adams PW, Orosz CG.

JAMA. 1997 Dec 10;278(22):1993-9. Review.

PMID:
9396662
24.

Expression of chemokine genes during rejection and long-term acceptance of cardiac allografts.

Fairchild RL, VanBuskirk AM, Kondo T, Wakely ME, Orosz CG.

Transplantation. 1997 Jun 27;63(12):1807-12.

PMID:
9210509
25.

Alloreactive delayed-type hypersensitivity in graft recipients: complexity of responses and divergence from acute rejection.

Sirak J, Orosz CG, Wakely E, VanBuskirk AM.

Transplantation. 1997 May 15;63(9):1300-7.

PMID:
9158025
26.
27.

Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival?

Piccotti JR, Chan SY, VanBuskirk AM, Eichwald EJ, Bishop DK.

Transplantation. 1997 Mar 15;63(5):619-24. Review. No abstract available.

PMID:
9075827
28.

Acute rejection of cardiac allografts by noncytolytic CD4(+) T cell populations.

VanBuskirk AM, Wakely ME, Orosz CG.

Transplantation. 1996 Jul 27;62(2):300-2.

PMID:
8755833
29.
30.

Prevention of murine cardiac allograft rejection with gallium nitrate. Comparison with anti-CD4 monoclonal antibody.

Orosz CG, Wakely E, Bergese SD, VanBuskirk AM, Ferguson RM, Mullet D, Apseloff G, Gerber N.

Transplantation. 1996 Mar 15;61(5):783-91.

PMID:
8607184
31.

Nonradioactive alternative to clinical mixed lymphocyte reaction.

VanBuskirk AM, Adams PW, Orosz CG.

Hum Immunol. 1995 May;43(1):38-44.

PMID:
7558927
32.

Immunologic characterization of murine cardiac allograft recipients with long-term graft survival due to anti-VCAM-1 or anti-CD4 monoclonal antibody therapy.

Orosz CG, Bergese SD, Huang EH, Vanbuskirk AM.

Transplant Proc. 1995 Feb;27(1):387-8. No abstract available.

PMID:
7533414
33.

Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.

Kaumaya PT, Kobs-Conrad S, Seo YH, Lee H, VanBuskirk AM, Feng N, Sheridan JF, Stevens V.

J Mol Recognit. 1993 Jun;6(2):81-94.

PMID:
7508238
34.

Design and immunological properties of topographic immunogenic determinants of a protein antigen (LDH-C4) as vaccines.

Kaumaya PT, VanBuskirk AM, Goldberg E, Pierce SK.

J Biol Chem. 1992 Mar 25;267(9):6338-46.

35.

Cellular and subcellular distribution of PBP72/74, a peptide-binding protein that plays a role in antigen processing.

VanBuskirk AM, DeNagel DC, Guagliardi LE, Brodsky FM, Pierce SK.

J Immunol. 1991 Jan 15;146(2):500-6.

PMID:
1987275
36.

A role for heat shock proteins in antigen processing and presentation.

Pierce SK, DeNagel DC, VanBuskirk AM.

Curr Top Microbiol Immunol. 1991;167:83-92. Review. No abstract available.

PMID:
2055100

Supplemental Content

Loading ...
Support Center